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Abstract Dendritic cells (DCs) are ideal accessory cells in the
developing ¢eld of gene therapy. Although viral transfection of
DCs has become widespread, non-viral transfection of DCs has
shown disappointing results. Recently, a new technique for
transfecting primary cells has become available ^ the Amaxa
Nucleofector1. Here, we describe the use of this device in the
successful non-viral transfection of human monocyte-derived
DCs. Using enhanced green £uorescent protein as a reporter
gene DCs were transfectable with e⁄ciencies approaching
60%, remaining responsive to lipopolysaccharide-stimulated cy-
tokine production in short-term experiments (though long-term
functional assays were hampered by loss of viability). Although
these data demonstrate the ease and e⁄ciency with which hu-
man monocyte-derived DCs can now be non-virally transfected,
they also suggest the limitations of this technology due to the
gradual loss of cell viability. The potential use of this system in
the development of DC-based cell and gene therapies will be
hampered until cell viability can be maintained.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Dendritic cells (DCs) are bone marrow-derived leukocytes
whose primary function is that of antigen capture and pre-
sentation for the initiation of a primary immune response [1^
3]. Given their pivotal role in antigen processing as well as
their important role in tumor immunology [4^12], the use of
ex vivo-manipulated human DCs in augmenting the immune
response is an attractive approach in the growing ¢elds of cell-
based and gene therapies.
The use of genetically modi¢ed primary DCs for research or
therapeutic uses has been greatly hampered by the di⁄culties
involved in their successful transfection. Although several au-
thors have reported the use and feasibility of retroviral trans-
duction of human DCs in vitro [4,7,13,14], the safety concerns
inherent in the use of engineered viruses has limited their use
in the clinical setting. Moreover, low transfection e⁄ciencies
with non-viral vectors [15^19] have severely limited this area
of therapeutic research. Recently, a new technology was de-
veloped that allows the directed electroporation of DNA into
the nucleus. This new technology ^ nucleofection ^ is thought
to be capable of generating transfectants of non-proliferating
and otherwise di⁄cult-to-transfect primary cells. We report
here on the optimization of a non-viral nucleofection protocol
as a successful method of DC gene transfer that is capable of
achieving high e⁄ciencies with limited short-term toxicity to
the cell.
2. Materials and methods
2.1. Cell culture
Human peripheral blood monocytes were obtained from healthy
volunteers by leukapheresis. Monocytes were puri¢ed from mononu-
clear cells by Ficoll-hypaque sedimentation followed by countercur-
rent centrifugal elutriation [20,21]. Monocytes (s 95% CD14þ) were
resuspended at a density of 1.5^2.0U106 cells per ml in complete
medium ^ Dulbecco’s modi¢ed Eagle’s medium (DMEM; Life Tech-
nologies, Rockville, MD, USA) containing 10% fetal bovine serum
(BioWhittaker, Walkersville, MD, USA), 10 Wg/ml gentamicin, 100
ng/ml recombinant human granulocyte/macrophage colony-stimulat-
ing factor (generously provided by Immunex Corporation, Seattle,
WA, USA) and 100 ng/ml recombinant human interleukin (IL) 4
(generously provided by Schering Plough Corporation, Kenilworth,
NJ, USA), and cultured at 37‡C for a minimum of 6 days to allow
for di¡erentiation into DCs.
2.2. Transfection of DCs
A red-shifted humanized variant of the green £uorescent protein
(GFP) gene driven by the CMV promoter (pEGFP-N1) obtained
from Clontech (Palo Alto, CA, USA) was used to gauge transfection
e⁄ciency. pEGFP-N1 was propagated in Escherichia coli strain DH5K
(Gibco BRL, Grand Island, NY, USA) and puri¢ed by double band-
ing on cesium chloride gradients. The non-adherent DCs were har-
vested at days 6 or 7 of culture, washed once in cold phosphate-bu¡-
ered saline, and resuspended in the speci¢ed electroporation bu¡er to
a ¢nal concentration of 2U107 cells/ml. Five Wg of plasmid DNA was
mixed with 0.1 ml of cell suspension, transferred to a 2.0 mm electro-
poration cuvette, and nucleofected with an Amaxa Nucleofector1
apparatus (Amaxa, Cologne, Germany) as described. DNA quantity,
cell concentration, and bu¡er volume were kept constant throughout
all experiments. After electroporation, cells were immediately trans-
ferred to 2.0 ml of complete medium, and cultured in six-well plates at
37‡C until analysis. Viability of cells immediately after transfection
was determined by trypan blue exclusion; at all other time points
viability was determined by propidium iodide staining. Validation of
the GFP data was performed using a dominant-negative MyD88 con-
struct tagged with GFP that was kindly provided by Dr. Cynthia
Leifer, NCI, NIH.
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2.3. EGFP expression analysis
EGFP expression in transfected cells was determined at speci¢c
times post nucleofection by FACS analysis. DCs were harvested
and resuspended in ice-cold Hanks’ balanced salt solution (Life Tech-
nologies) containing 0.1% bovine serum albumin (Life Technologies)
and 0.1% sodium azide (Aldrich, Milwaukee, WI, USA). EGFP ex-
pression was determined by excitation at 488 nm and analysis at 511
nm. Cellular £uorescence and viability (propidium iodide exclusion)
were monitored in a FACSCalibur0 (Becton Dickinson, Mans¢eld,
MA, USA) and analyzed using the CellQuest software provided by
the manufacturer.
2.4. Immunophenotyping of DCs
DCs were also analyzed for expression of di¡erentiation and acti-
vation markers. Cells were stained with phycoerythrin-conjugated
monoclonal antibodies raised against the following human surface
antigens (all antibodies obtained from Pharmingen, San Diego, CA,
USA): CD14 (M5E2, mouse IgG2a), CD11c (B-ly6, mouse IgG1),
CD80 (L307.4, mouse IgG1), HLA-DR (G46-6, mouse IgG2a),
CD40 (5C3, mouse IgG1), CD83 (HB15e, mouse IgG1), CD86
(IT2.2, mouse IgG2b), and appropriate isotype controls. Cells (105
per assay) were incubated with the respective antibody (2.5 Wg per
sample) for 30^45 min at 4‡C prior to washing. Cellular £uorescence
was monitored as described previously. DCs, gated by forward and
side scatter, expressed high levels of CD11c but were negative for
CD14 (data not shown).
2.5. Functional analysis of transfected DCs
To detect intracellular cytokine production, untreated or trans-
fected cells were exposed to lipopolysaccharide (LPS, 1 Wg/ml), and
1 h later, the proteosome inhibitor brefeldin A (GolgiPlug, Pharmin-
gen) was added for an additional 5 h. Cells were then ¢xed and
permeabilized using a Cyto¢x/Cytoperm Kit (Pharmingen) according
to the manufacturer’s instructions, and stained with FITC-labeled
mouse anti-human monoclonal antibodies against IL-1L (IgG1), tu-
mor necrosis factor K (TNFK) (IgG1), IL-6 (IgG2b), IL-12 (IgG1),
and their respective isotype controls (all RpD Systems, Minneapolis,
MN, USA). Cellular £uorescence was monitored and analyzed as
described.
3. Results
3.1. Optimization of cDNA transfection in DCs
Immature DCs derived from human monocytes were used
to optimize the nucleofection conditions. Over 80 separate
conditions were tested, and transfection e⁄ciencies were de-
termined by FACS analysis of EGFP expression. As shown in
Fig. 1 (which represents a subset of the overall data), analysis
of cells 24 h post transfection demonstrated a high percentage
of EGFP expression under optimized experimental conditions.
Of the various electrical settings and bu¡er conditions used,
the best nucleofection e⁄ciencies were observed with protocol
T-01 and both bu¡ers T and V (48.0 S 8.2%, range of 30^60%,
and 44.2 S 7.0%, range of 25^59%, respectively). These two
sets of conditions were used in subsequent experiments.
3.2. Kinetics of EGFP expression
Since the speci¢ed conditions demonstrated a signi¢cant
level of EGFP expression at 24 h post transfection, the ki-
netics of that response was determined as a function of time.
Fig. 1. Expression of EGFP in nucleofected DCs. Day 7 monocyte-
derived DCs were resuspended (2U107 cells/ml) in bu¡er R (right
cross hatch), bu¡er T (left cross hatch), or bu¡er V (stippled), and
nucleofected using the settings described. Cells were then transferred
to complete DMEM, and incubated at 5% CO2 and 37‡C for 24 h.
Cellular expression of EGFP was determined by FACS analysis as
described. Data represent the mean and its standard error of four
to seven individual experiments.
Fig. 2. Time course of EGFP expression in nucleofected DCs. Day
7 monocyte-derived DCs were resuspended in bu¡er V, and nucleo-
fected using protocol T-01. Cells were then transferred to complete
medium and incubated as described. Cells were removed at the
speci¢ed times post treatment, and expression of EGFP as well as
viability determined by FACS analysis. Numbers in the upper right
indicate the percentage of EGFP-expressing or viable cells, respec-
tively, and are representative of a minimum of four experiments.
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Using the electrical program T-01 and bu¡er V, cells were
transfected with EGFP and the e⁄ciency of transfection de-
termined up to 48 h post treatment. As seen in Fig. 2, the
e⁄ciency of DC transfection was as high as 30% as early as 4 h
after nucleofection. By 8 h post nucleofection transfection
e⁄ciency under these conditions was up to 55%, where it
remained over the next 24 h (Fig. 2). By 48 h post nucleofec-
tion the transfection e⁄ciency was still high, reaching 40%.
The cell viability over this time period re£ected the damage
that generally occurs upon transfection ^ during the initial 8 h
post treatment cell viability remained high, staying in the 80^
90% range. By 24 h however, cell viability had dropped to
under 40%, continuing to drop to 14% by 48 h post treatment.
3.3. E¡ect of nucleofection on phenotypic characteristics of
immature DCs
Given the cellular damage that these transfection methods
incur over time, an important consideration when working
with any cell type but especially DCs is the impact of any
treatment on cell phenotype and function. To assess the e¡ect
of nucleofection on these parameters, we performed FACS
analysis on untransfected or transfected DCs 24 h after treat-
ment in either bu¡er T or bu¡er V (Fig. 3). Under these
conditions nucleofection did not induce DC maturation or
activation. With the exception of a slight but consistent
down-regulation of CD80, the phenotype remained stable
over 24 h after treatment.
3.4. LPS-induced activation and di¡erentiation of
transfected DCs
To assess the ability of transfected cells to respond in a
functional manner to external stimuli untreated and EGFP-
transfected DCs were stimulated with LPS, and cytokine pro-
duction was determined by intracellular cytokine staining. As
shown in Fig. 4, the nucleofection procedure alone did not
induce any of the in£ammatory cytokines tested (TNFK, IL-
1L, IL-6, IL-12), whereas exposure to LPS induced high levels
of TNFK and IL-1L, moderate levels of IL-6, and no IL-12
(Fig. 4). Transfected cells that were subsequently treated with
LPS exhibited a di¡erent pattern of cytokine production, in-
dicating that nucleofection a¡ects gene expression in DCs
(Fig. 4). Whereas IL-1L, TNFK and IL-6 responses to LPS
in nucleofected DCs were substantially decreased, IL-12 was
induced. This latter ¢nding is of particular interest considering
the important role of IL-12 in the induction of Th1 T cell
responses. A more dramatic decrease in LPS responsiveness
was observed in regard to LPS-induced phenotypic character-
istics. Transfected immature DCs subsequently treated with
LPS failed to undergo phenotypic activation or maturation
as evidenced by the unchanged surface expression of the cos-
timulatory molecules CD40 and CD80, and the activation
marker CD83 (data not shown).
3.5. Nucleofection of mature DCs
Given that the lack of phenotypic maturation and activa-
Fig. 3. Surface expression of di¡erentiation markers on monocyte-derived DCs. Day 7 monocyte-derived DCs were resuspended in bu¡er T or
bu¡er V and either nucleofected using protocol T-01 or left untouched (‘no TX’). Cells were then transferred to complete medium and incuba-
ted as described. After 24 h cells were stained for surface expression of CD40, CD80, CD86, and CD83 as described in Section 2. Numbers
represent the mean £uorescence intensity of the histograms. Shown are the results of one representative experiment out of a minimum of four
experiments.
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tion after nucleofection would be a major drawback for many
DC applications, we investigated whether matured DCs can
be nucleofected e⁄ciently, and whether the procedure con-
serves their mature phenotype. Immature DCs were pretreated
with LPS for 24 h, transfected, and assayed for marker ex-
pression to demonstrate terminal maturation (Fig. 5A). Using
the optimized transfection procedures identi¢ed earlier, trans-
fection e⁄ciencies reached up to 39% at 8 h after nucleofec-
tion (Fig. 5B). At 24 h post nucleofection, cells retained their
mature phenotype, and exhibited similar viability and EGFP
expression as their immature counterparts (data not shown).
3.6. Validation of DC transfection e⁄ciency with GFP
To determine whether the data obtained with GFP as the
transfecting construct can be expanded to other plasmids, we
attempted to transfect a similar pEGFP-N1 construct into
which amino acids 152^296 of the MyD88 sequence (corre-
sponding to the C-terminal binding domain but lacking the
N-terminal death domain) was subcloned. As shown in Fig. 6,
high transfection e⁄ciency and excellent viability were ob-
served within 6 h post transfection, demonstrating the ability
to apply these methodologies to di¡erent constructs.
4. Discussion
The genetic manipulation of DCs has become a major focus
of research, due to its potential in the development of vaccines
for treatment of cancer, chronic, and infectious diseases.
Though the use of viral transduction has been shown to be
e¡ective for this purpose [4,10,11,22^28], the application of
these methods has certain disadvantages. Besides an increase
in the immunogenicity of virus-manipulated DCs due to the
transfer of viral proteins [29^32], the risk of oncogenesis or
mutagenesis from the insertion of the viral genome into host
cell DNA remains a serious safety concern [33^35]. On the
other hand, the non-viral transfection of DCs has proven to
be di⁄cult, partially due to the fact that these cells are non-
dividing. Thus, reports of DC transfection by non-viral meth-
ods have been few: electroporation of DCs, when successful,
has consistently given transfection e⁄ciencies in the range of
10^15% [15^19,36^38]. Attempts at lipid-mediated transfer of
genetic material into DCs have provided similar results [39^
44].
Here, we report on a simple method of electroporation of
DCs that provides a rapid and e⁄cient way of transferring
genetic material into monocyte-derived immature and mature
DCs. This transfection procedure retains most of the pheno-
typic characteristics of DCs and their ability to secrete in£am-
matory cytokine upon exposure to external stimuli. However,
it has certain deleterious e¡ects on DCs ^ most signi¢cantly
the limited survival over 48 h and their unresponsiveness to
LPS-induced maturation. The latter problem could be circum-
vented by nucleofection of previously matured DCs.
The low viability at 24 h seen in our experiments is similar
to that observed with other electroporation systems and other
cell types. It might be partially attributed to the physical
damage that occurs when cells are exposed to short-duration
but high-intensity electrical discharges. Whether the changes
Fig. 4. Induction of in£ammatory cytokines in nucleofected DCs. Day 7 monocyte-derived DCs were nucleofected as described, and immedi-
ately exposed to LPS (1 Wg/ml) for 1 h followed by brefeldin A for 5 h. The intracellular cytokines TNFK, IL-1L, IL-6 and IL-12 were quanti-
¢ed by £ow cytometry (FL1) as described in Section 2. Numbers represent the percentage of cytokine-producing DCs, and are representative of
three separate experiments.
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in DC responsiveness to LPS stimulation re£ect the cellular
damage that ultimately results in the observed decreases in
viability, or a more direct inhibition of some cellular pathway,
is unknown. In any case, the high transfection e⁄ciency ob-
tained within the ¢rst 24 h makes nucleofection a powerful
procedure for gene transfer into DCs in short-term experi-
ments. Furthermore, despite the low survival at later time
points, the continued high transfection e⁄ciency might
make this method useful even for some long-term assays
and might provide distinct advantages over other methods
of transfection that provide higher rates of viability but result
in signi¢cantly lower transfection e⁄ciencies.
For the time being, the nature of the electrical parameters
that the Amaxa Nucleofector1 uses and the composition of
the bu¡ers that are required remain a proprietary secret.
However, this system remains the only successful method to
date of achieving a rapid and e⁄cient short-term transfer of
plasmid DNA into monocyte-derived immature or mature
DCs, suggestive of the promise it lends to the developing ¢elds
of gene therapy and DC research.
Fig. 5. Nucleofection of LPS-matured DC. Immature DCs (dotted lines) were exposed to LPS (1 Wg/ml) for 24 h and maturation (heavy lines)
determined by £ow cytometry (A). LPS-matured DCs (B) were assayed for EGFP expression and viability before or 4 and 8 h after nucleofec-
tion. EGFP expression in nucleofected cells (heavy line) is shown as compared to mock-transfected cells (dotted line). Numbers in the upper
right indicate percentage of EGFP-positive or viable cells, respectively. Shown are results of one representative experiment out of three.
6
Fig. 6. Expression of DN-MyD88-GFP in nucleofected DCs. Day 7
monocyte-derived DCs were resuspended in bu¡er V, and nucleo-
fected using protocol T-01. Cells were then transferred to complete
medium and incubated as described. Cells were removed at 6 h post
treatment, and expression of pEGFP-N1 and DN-MyD88-GFP
(pEGFP-N1 into which a portion of MyD88 was subcloned) as well
as viability determined by FACS analysis. Numbers in the upper
right indicate the percentage of GFP-expressing or viable cells, re-
spectively.
FEBS 27055 28-2-03
P. Lenz et al./FEBS Letters 538 (2003) 149^154 153
Acknowledgements: The authors would like to thank Drs. David
Frucht, and Wendy Weinberg for critical review of the manuscript.
S.M.B. was supported by an appointment in the Postgraduate Re-
search Participation Program from the Oak Ridge Institute for Sci-
ence and Education.
References
[1] Banchereau, J. and Steinman, R.M. (1998) Nature 392, 245.
[2] Marland, G., Bakker, A.B., Adema, G. and Figdor, C.G. (1996)
Stem Cells 14, 501^507.
[3] Steinman, R.M. (1991) Annu. Rev. Immunol. 9, 271^296.
[4] Brossart, P., Goldrath, A.W., Butz, E.A., Martin, S. and Bevan,
M.J. (1997) J. Immunol. 158, 3270^3276.
[5] Grabbe, S., Beissert, S., Schwarz, T. and Granstein, R.D. (1995)
Immunol. Today 16, 117^121.
[6] Ju, D.W., Tao, Q., Lou, G., Bai, M., He, L., Yang, Y. and Cao,
X. (2001) Cancer Res. 61, 3735^3740.
[7] Reeves, M.E., Royal, R.E., Lam, J.S., Rosenberg, S.A. and Hwu,
P. (1996) Cancer Res. 56, 5672^5677.
[8] Shibagaki, N. and Udey, M.C. (2002) J. Immunol. 168, 2393^
2401.
[9] Smith, S.G., Patel, P.M., Porte, J., Selby, P.J. and Jackson, A.M.
(2001) Clin. Cancer Res. 7, 4253^4261.
[10] Song, W., Kong, H.L., Carpenter, H., Torii, H., Granstein, R.,
Ra¢i, S., Moore, M.A. and Crystal, R.G. (1997) J. Exp. Med.
186, 1247^1256.
[11] Specht, J.M., Wang, G., Do, M.T., Lam, J.S., Royal, R.E.,
Reeves, M.E., Rosenberg, S.A. and Hwu, P. (1997) J. Exp.
Med. 186, 1213^1221.
[12] Xia, D.J. et al. (2002) Gene Ther. 9, 592^601.
[13] Aicher, A. et al. (1997) Exp. Hematol. 25, 39^44.
[14] Henderson, R.A., Nimgaonkar, M.T., Watkins, S.C., Robbins,
P.D., Ball, E.D. and Finn, O.J. (1996) Cancer Res. 56, 3763^
3770.
[15] Alijagic, S., Moller, P., Artuc, M., Jurgovsky, K., Czarnetzki,
B.M. and Schadendorf, D. (1995) Eur. J. Immunol. 25, 3100^
3107.
[16] Arthur, J.F. et al. (1997) Cancer Gene Ther. 4, 17^25.
[17] Lohmann, S., Galle, K., Knop, J. and Enk, A.H. (2000) Cancer
Gene Ther. 7, 605^614.
[18] Van Tendeloo, V.F. et al. (1998) Gene Ther. 5, 700^707.
[19] Van Tendeloo, V.F., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou,
M., Van Broeckhoven, C., Van Bockstaele, D.R. and Berneman,
Z.N. (2001) Blood 98, 49^56.
[20] Wahl, S.M., Katona, I.M., Stadler, B.M., Wilder, R.L., Helsel,
W.E. and Wahl, L.M. (1984) Cell Immunol. 85, 384^395.
[21] Wahl, L.M., Katona, I.M., Wilder, R.L., Winter, C.C., Haraoui,
B., Scher, I. and Wahl, S.M. (1984) Cell Immunol. 85, 373^383.
[22] Cui, Y., Golob, J., Kelleher, E., Ye, Z., Pardoll, D. and Cheng,
L. (2002) Blood 99, 399^408.
[23] Di Nicola, M. et al. (2000) Br. J. Haematol. 111, 344^350.
[24] Liu, Y., Santin, A.D., Mane, M., Chiriva-Internati, M., Parham,
G.P., Ravaggi, A. and Hermonat, P.L. (2000) J. Interferon Cy-
tokine Res. 20, 21^30.
[25] Liu, Y., Chiriva-Internati, M., Grizzi, F., Salati, E., Roman, J.J.,
Lim, S. and Hermonat, P.L. (2001) Cancer Gene Ther. 8, 948^
957.
[26] Negre, D. et al. (2000) Gene Ther. 7, 1613^1623.
[27] Ponnazhagan, S., Mahendra, G., Curiel, D.T. and Shaw, D.R.
(2001) J. Virol. 75, 9493^9501.
[28] Zhong, L., Granelli-Piperno, A., Pope, M., Ignatius, R., Lewis,
M.G., Frankel, S.S. and Steinman, R.M. (2000) Eur. J. Immunol.
30, 3281^3290.
[29] Jooss, K., Yang, Y., Fisher, K.J. and Wilson, J.M. (1998)
J. Virol. 72, 4212^4223.
[30] Trapnell, B.C. and Gorziglia, M. (1994) Curr. Opin. Biotechnol.
5, 617^625.
[31] Yang, Y., Li, Q., Ertl, H.C. and Wilson, J.M. (1995) J. Virol. 69,
2004^2015.
[32] Minche¡, M. et al. (2001) Crit. Rev. Oncol. Hematol. 39, 125^
132.
[33] Gordon, E.M. and Anderson, W.F. (1994) Curr. Opin. Biotech-
nol. 5, 611^616.
[34] Lu, D., Benjamin, R., Kim, M., Conry, R.M. and Curiel, D.T.
(1994) Cancer Gene Ther. 1, 245^252.
[35] Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S.,
Marincola, F.M., Leitner, W.W. and Restifo, N.P. (1999) Nat.
Med. 5, 823^827.
[36] Glasspool-Malone, J., Somiari, S., Drabick, J.J. and Malone,
R.W. (2000) Mol. Ther. 2, 140^146.
[37] Saeboe-Larssen, S., Fossberg, E. and Gaudernack, G. (2002)
J. Immunol. Methods 259, 191^203.
[38] Strobel, I., Berchtold, S., Gotze, A., Schulze, U., Schuler, G. and
Steinkasserer, A. (2000) Gene Ther. 7, 2028^2035.
[39] Diebold, S.S., Cotten, M., Wagner, E. and Zenke, M. (1998)
Adv. Exp. Med. Biol. 451, 449^455.
[40] Diebold, S.S., Kursa, M., Wagner, E., Cotten, M. and Zenke, M.
(1999) J. Biol. Chem. 274, 19087^19094.
[41] Diebold, S.S., Lehrmann, H., Kursa, M., Wagner, E., Cotten, M.
and Zenke, M. (1999) Hum. Gene Ther. 10, 775^786.
[42] Diebold, S.S., Cotten, M., Koch, N. and Zenke, M. (2001) Gene
Ther. 8, 487^493.
[43] Haines, A.M. et al. (2001) Gene Ther. 8, 99^110.
[44] Irvine, A.S. et al. (2000) Nat. Biotechnol. 18, 1273^1278.
FEBS 27055 28-2-03
P. Lenz et al./FEBS Letters 538 (2003) 149^154154
